

Technical Note

Not peer-reviewed version

Assessment of Blood-Brain Barrier Integrity Using Dyes and Tracers

[Carmen Munoz-Ballester](#) , Samantha Golf , Benjamin Heithoff , Kijana George , Stefanie Robel *

Posted Date: 5 September 2024

doi: 10.20944/preprints202409.0341.v1

Keywords: Blood-Brain Barrier; BBB; Dye; Tracer; Cadaverine; Impairment; Leakage; Permeability



Preprints.org is a free multidiscipline platform providing preprint service that is dedicated to making early versions of research outputs permanently available and citable. Preprints posted at Preprints.org appear in Web of Science, Crossref, Google Scholar, Scilit, Europe PMC.

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Technical Note

Assessment of Blood-Brain Barrier Integrity Using Dyes and Tracers

Carmen Muñoz-Ballester ^{1,†}, Samantha Golf ^{1,†}, Benjamin Heithoff ², Kijana George ² and Stefanie Robel ^{1,*}

¹ Department of Cell, Developmental and Integrative Biology, University of Alabama at Birmingham, Birmingham, AL, USA

² Fralin Biomedical Research Institute at Virginia Tech Carilion, Roanoke 24016, Virginia

* Correspondence: srob@uab.edu; Tel.: +1 205 975 3391

[†] Authors contributed equally to this publication.

Abstract: Under physiological conditions the blood-brain barrier (BBB) is required for regulating the passage of substances between the bloodstream and the brain. To date, disruption of the BBB has been associated with nearly all neurological diseases. Dye and tracer experiments have been used to assess BBB integrity for decades, yet quantitative assessment of these experiments has only recently been implemented. Further, interpretation of these results requires the consideration of tracer-specific properties. Here, we describe a protocol for evaluating BBB leakage using the small molecule cadaverine in quantitative way. We also cover advantages/disadvantages of using some reagents and highlight limitations in data interpretations based on assays used to assess BBB permeability.

Keywords: blood-brain barrier; BBB; Dye; tracer; cadaverine; impairment; leakage; permeability

1. Introduction

Why the BBB is important?

The vasculature of the central nervous system is unique because of its barrier properties that prevent unregulated passage of ions, molecules, and cells. These barrier properties include low transcytosis levels and a lack of paracellular passage [1]. Tight junctions are expressed in endothelial cells to ensure the physical exclusion of the blood content from the brain. Disruption of these endothelial tight junctions compromises the integrity of the blood-brain barrier (BBB), resulting in increased permeability. This permeability is associated with almost all brain disorders (under review in [2]).

BBB permeability is often assessed using intravenous injection of fluorescent tracers or dyes of different molecular weights. These tracers are normally excluded from entering the brain due to the function of the BBB. This is an excellent assay to assess BBB permeability as long as the experimenter is clear on the limitations of the respective tracers and interpretations that can be drawn from the results of the experiments.

Traditionally, Evans blue was used to assess BBB permeability. Evans blue is an azo dye that appears blue in brightfield microscopy but also fluoresces with emission at 680nm (far red) and can thus be analyzed using fluorescent microscopy. Evans blue binds to albumin (66.5 kDa) and is thus often thought to reflect BBB permeability to molecules of the size of albumin. Yet, contrary to common belief, there is a significant amount of free Evans blue (~960 Da) present at the typically used concentration of 2% (w/v) and 4mL/kg bodyweight [3], which needs to be considered when interpreting the extent and nature of BBB damage. In its free form, Evans blue can be taken up by cells (often neurons), which makes assessment of small BBB damage easier. Bound to albumin, Evans blue may be entering the brain not only paracellularly due to impaired tight junctions or vasculature but can also enter via transport or increased transcytosis [4]. Evans blue inhibits glutamate uptake via EAATs and also is a kainate receptor antagonist [5, 6]. Thus, it should not be used in combination

with electrophysiology experiments. Lastly, Evans blue has been reported to have toxic effects on the endothelium within hours after administration suggesting that caution has to be exercised when designing and interpreting Evans blue experiments [3].

These limitations can be circumvented by using different tracers. Albumin coupled to fluorophores can assess changes in vascular and tight junctional integrity when they are so large as to allow entry of molecules 66.5 kDa and smaller. Yet this approach can also indicate changes in transcytosis or transcellular transport because albumin is a substrate for transporters and can cross the endothelium via transcytosis (reviewed in [7]). Dextran of varying molecular weights (3 to 2000 kDa) coupled to fluorophores are useful for assessment of the extent of paracellular BBB permeability (Fig. 1). Cadaverine, a molecule of similar size as free Evans blue dependent on the fluorophore that it is coupled to (640 Da when coupled to Alexa Fluor 488 and 950 Da when coupled to Alexa Fluor 555), enters the brain paracellularly when the vasculature or tight junctions are damaged. Importantly, cadaverine enters the healthy brain parenchyma in some brain areas, i.e. the hypothalamic median eminence, which has fenestrated capillaries and can thus serve as a positive control. In aging animals, cadaverine is leakier [8] and needs to be quantitatively compared to the experimental condition. Alexa Fluor 488, Alexa Fluor 555 and Alexa Fluor 647 contain carboxyl and/or sulfonic groups, which render the dextran or cadaverine conjugate PFA-fixable, so that there is no diffusion within the tissue after perfusion of the animal. In this protocol, we provide a quantitative method for assessing BBB permeability using the small molecule cadaverine, that we have successfully optimized in the last years [9, 10].




Figure 1. Peripheral injection of dextran for assessing extent of paracellular BBB permeability. Fluorophore-conjugated dextran of 10kDa size (red) permeating from vasculature into neural tissue in cortical regions overlapping areas where glutamate transporter 1 (Glt1, cyan) exhibits decreased expression after a traumatic brain injury.

2. Materials

1. 1X phosphate buffered saline (PBS), pH 7.3
2. 4% paraformaldehyde (PFA), diluted in 1X PBS pH 7.3
3. Surgical tools: large surgical scissors, small dissection scissors, curved forceps, spatula (with microspoon), serrated blunt forceps, vacuette blood collection set (see **Note 1**)
4. 15 mL Falcon tubes
5. Vibratome
6. 24-well plates
7. 10X PO4 Buffer, pH 7.2-7.4: 65g $\text{NaH}_2\text{PO}_4 \times \text{H}_2\text{O}$, 15g NaOH, 2N HCl, distilled H_2O to total volume of 500mL
8. Glycerol-based storing solution: 150mL Glycerol, 150mL Ethylene Glycol, 50mL 10X PO4 Buffer pH 7.2-7.4, 150mL distilled H_2O
9. Rocking platform at room temperature
10. Paintbrushes
11. Positive charged glass microscope slides

12. Mounting media (DAPI-free)

13. Coverslips

14. Clear nail polish

15. Epifluorescence microscope

16. Confocal microscope

17. Image analysis software
1. Fluorophore-conjugated cadaverine (*see Table 1*)

2. 1X PBS, sterile

3. Isoflurane

4. Vaporizer for anesthesia (for example Somnoflow® low-flow electronic vaporizer)

5. Anesthesia box

6. Insulin syringes

Table 1. List of dyes required for the outlined methods for analysis of BBB dysfunction.

Dyes				
Name	Manufacturer	Catalog #	RRID	Concentration
DAPI	ThermoFisher	D1306	AB_2629482	1:1000
AF555 Cadaverine	ThermoFisher	A30677	N/A	0.33mg/mouse
AF488 Cadaverine	ThermoFisher	A30676	N/A	0.33mg/mouse

3. Methods

This protocol describes two methods to quantify leakage of cadaverine conjugated to a fluorophore (*see Note 2*).

3.1. Tissue preparation and imaging

1. Resuspend cadaverine conjugated to a fluorophore in sterile PBS solution at a concentration of 3.3 mg/1 mL.

2. Put the mouse under anesthesia with isoflurane 3% for 4 min in the anesthesia box.

3. Remove animal from anesthesia chamber and retroorbitally inject 100 µL of resuspended cadaverine with an insulin syringe. Start 30 min timer (*see Note 3, Note 4, Note 5*).

4. Place mouse back in home cage for 30 min.

5. When 30 min are up, transcardially perfuse the anesthetized mouse as described in [11].

6. Extract the brain from the skull and immerse it in 15 mL Falcon tube with 10 mL of 4% PFA overnight at 4°C.

7. The following day, wash the brain with filtered PBS and store the washed brain in filtered PBS (*see Note 6*).

8. Section the brains using a vibratome in 50 µm slices. Section can be kept at 4°C in PBS for short term storage. For long term storage, slices can be kept in 1.5 mL Eppendorf tubes in a glycerol-based storing solution at -20°C (*see Note 7*).

9. This can be combined with co-staining with antibodies, avoiding the use of secondary fluorophores with the same color as cadaverine.

10. Using a paint brush transfer brain slices into a well of a 24-well plate with DAPI 1:1000 in PBS.

11. Incubate sections in DAPI for 4-5 minutes on a rocking platform at room temperature.

12. Wash sections in PBS twice for 10 minutes on a rocking platform (*see Note 8*).

13. Check the staining on one section on a slide in a fluorescence microscope (*see Note 9*).

14. Mount sections on positively charged glass slides. When sections are dried attach coverslip with water-based fluorescence-protective mounting media (*see Note 10*). Apply clear nail polish to coat the edges of the coverslip in order to seal it in place. Let it dry overnight.

15. After mounting the sections, acquire a stitch image of the cortex on a confocal microscope at 10x magnification and 1024x1024 resolution. Set blending at 15%. We recommend sampling multiple

slices per animal, for having an accurate estimation of expression across the entire cortex, we most often collect a total of 3-5 sections.

3.2. Manual assessment of cadaverine leakage in cortex (see Note 11) (Fig. 2).

1. In an image analysis software (for example FIJI) draw region of interest (ROI) around the entire cortex, using the corpus callosum as a boundary. The DAPI channel can also be used to determine this area.
2. Measure the area of the ROI. This is the “total cortex area” for this slice.
3. Draw free-hand regions of interest around the cadaverine-positive cells. Selection criteria: cadaverine positive cells are brighter than background, cadaverine positive cells are clustered in reasonably close proximity to each other, there are greater than 10 cadaverine positive cells within the ROI. Continue until all ROI areas are outlined.
4. Measure the total the cortical area covered by these cadaverine positive ROIs. This is going to be the “total leakage area” for this slice.
5. Repeat steps 1-4 with all of the acquired images.
6. Calculate the percent of cadaverine leakage in the cortex using this equation:

$$\text{Percent leakage} = \frac{\text{Total leakage area of 5 slices}}{\text{Total cortex area of 5 slices}} \times 100$$




Figure 2. Step-by-step procedure for manual quantification of cadaverine leakage in mouse brain cortex. (a) Selection of the whole cortex using free-hand area selection. The selected area is encircled by a yellow line. This area will be measured. (b) Visual identification of large cadaverine positive areas. Cadaverine (red) is located in neuronal soma of areas of leakage and identified by the experimenter. (c) Selection of the cadaverine positive area using the free-hand area selection. The selected area appears surrounded by a yellow line. This area will also be measured. (d) Visualization of small areas of cadaverine leakage in cortex. In these areas cells appear more disperse. (e) Selection of the disperse cadaverine area. The cadaverine positive area is surrounded by a yellow line. The area encircled is measured. OB: olfactory bulb. V: ventricle.

3.3. Automated assessment of cadaverine leakage in cortex (Fig. 3).

1. This method selects leakage areas based on areas and shape. This method is more prone to omitting clusters of cadaverine positive cells, which tend to be excluded along blood vessels when using size exclusion but it reduces experimenter bias.
2. Draw a freehand ROI around the cortex. Use the corpus callosum as a boundary and avoid including bright blood vessels on the edge of the slice. Measure the area of this ROI. This parameter will be “total cortex area”.
3. Threshold the image such as cadaverine-positive cells are clearly highlighted. At this stage, some few blood vessels might be also selected. They will be excluded in further analysis (*see Note 12*).
4. Make a binary of the threshold image.
5. Adjust size and circularity to include only cadaverine-positive cells. Examine the generated mask and compare to original image for accuracy. Adjusting circularity helps exclude blood vessels.
6. Measure the area covered by the mask. This parameter will be “total leakage area”.
7. Repeat steps 1-5 in 5 slices per animal.
8. Calculate the percent of cadaverine leakage in the cortex using this equation:

$$\text{Percent leakage} = \frac{\text{Total leakage area of 5 slices}}{\text{Total cortex area of 5 slices}} \times 100$$




Figure 3. Procedure for automated quantification of cadaverine leakage in mouse brain cortex. (a) Stitched image of the cadaverine signal in cortex. A yellow square indicates the zoomed area. The cortex area will be encircled with a yellow line and the area measured. (b) Zoomed area of cortex showing a cadaverine positive area. (c) Same area after binarizing the cadaverine positive pixels. The

area covered by these positive pixels will be quantified and divided by the total area of the cortex. (d) Same area as in (c) after adjustment by circularity for excluding blood vessels. Some information is lost but no specific signal is eliminated in the process.

4. Notes

1. Once tools have come in contact with PFA, they can no longer be used for *in vivo* procedures or with unfixed tissue and cells.
2. This methodology has specifically been validated with cadaverine conjugated to Alexa Fluor 488 and 555.
3. Injections into the retroorbital sinus are easier to learn and more reliable than tail vein injections. If the retroorbital injection worked well, a change of color can be observed in the mouse as the cadaverine is distributed in the blood. Urine changes color also. If the retroorbital injection is not performed well, bleeding and swelling around the eye can be observed. This can happen if the experimenter did not reach the retro-orbital sinus with the syringe.
4. Ensure to not exceed the maximum volume that can be injected intravenously (≤ 5 ml/kg or ~ 125 μ L in a 25g mouse). Higher amounts can lead to volume overload resulting in high blood pressure, vascular and organ damage that impact experimental results.
5. Cadaverine can remain in the brain for longer than 30 min after injection, but the fluorescence levels decrease with time and are more difficultly distinguished after 4 hours after the injection. In Fig. 4 we compared the fluorescence levels of cadaverine administered 30 min, 4 hours, 1 day and 3 days before the perfusion and best results were obtained when cadaverine was injected 30 min before the injection. Thus, cadaverine is not a great solution to label where BBB damage initially occurs when tissue fixation takes place days later.
6. PBS should be filtered through a sterile 0.2 μ m filter.
7. If brain slices were stored in glycerol-based storing solution before starting the staining, wash the slices in PBS twice for 10 min at room temperature in 24 well plates.
8. For washing steps, transfer the sections to a different well with the washing solution using a paint brush.
9. If blood vessels appear fluorescent throughout the cortex (due to a suboptimal perfusion that did not flush all the dye out of the vasculature), exclude the animal from further analysis.
10. Make sure that the thickness of the coverslip is compatible with the objective that will be used. Most objectives require coverslips of number 1.5, which have a thickness between 0.16 - 0.19 mm.
11. Manual quantification of cadaverine leakage is fast but can be prone to bias because the cadaverine positive area that is selected is subjective to the experimenter.
12. It may be appropriate to use different analysis parameters for thresholding cadaverine positive cells across slices.




Figure 4. Comparison of cadaverine fluorescence levels at several timepoints following retroorbital administration. (a) Experimental timeline: cadaverine conjugated to Alexa Fluor 555 (Cad-A555, red) was retroorbitally injected immediately after a single weight drop traumatic brain injury (TBIx1) followed by retroorbital injection of cadaverine conjugated to Alexa Fluor 488 (Cad-A488, green) immediately after TBIx1, 30 min post injury, 4 hours post injury (4hpi), 1 day post injury (1dpi), or 3dpi. (b) Representative images of Cad-A555 (red) and Cad-A488 (green), injected at timepoints outline in a, overlaid with staining for glutamate transporter 1 (Glt1, cyan).

Acknowledgments: The work was supported by the National Institute of Neurological Disorders and Stroke (grant R01NS121145).

References

1. Ayloo S, Gu C (2019) Transcytosis at the Blood-Brain Barrier. *Curr Opin Neurobiol* 57:32–38. <https://doi.org/10.1016/j.conb.2018.12.014>
2. Profaci CP, Munji RN, Pulido RS, Daneman R (2020) The blood–brain barrier in health and disease: Important unanswered questions. *J Exp Med* 217:e20190062. <https://doi.org/10.1084/jem.20190062>
3. Saunders NR, Dziegielewska KM, Möllgård K, Habgood MD (2015) Markers for blood-brain barrier integrity: how appropriate is Evans blue in the twenty-first century and what are the alternatives? *Front Neurosci* 9:385. <https://doi.org/10.3389/fnins.2015.00385>
4. Davis AA (2020) Plasma proteins have a ticket to ride the blood-brain barrier. *Science Translational Medicine* 12:eabd3610. <https://doi.org/10.1126/scitranslmed.abd3610>

5. Roseth S, Fykse EM, Fonnum F (1995) Uptake of L-glutamate into rat brain synaptic vesicles: effect of inhibitors that bind specifically to the glutamate transporter. *J Neurochem* 65:96–103. <https://doi.org/10.1046/j.1471-4159.1995.65010096.x>
6. Schürmann B, Wu X, Dietzel ID, Lessmann V (1997) Differential modulation of AMPA receptor mediated currents by evans blue in postnatal rat hippocampal neurones. *Br J Pharmacol* 121:237–247. <https://doi.org/10.1038/sj.bjp.0701125>
7. Merlot AM, Kalinowski DS, Richardson DR (2014) Unraveling the mysteries of serum albumin – more than just a serum protein. *Front Physiol* 5:. <https://doi.org/10.3389/fphys.2014.00299>
8. Mills WA, Woo AM, Jiang S, et al (2022) Astrocyte plasticity in mice ensures continued endfoot coverage of cerebral blood vessels following injury and declines with age. *Nat Commun* 13:1794. <https://doi.org/10.1038/s41467-022-29475-2>
9. Heithoff BP, George KK, Phares AN, et al (2021) Astrocytes are necessary for blood-brain barrier maintenance in the adult mouse brain. *Glia* 69:436–472. <https://doi.org/10.1002/glia.23908>
10. George KK, Heithoff BP, Shandra O, Robel S (2022) Mild Traumatic Brain Injury/Concussion Initiates an Atypical Astrocyte Response Caused by Blood-Brain Barrier Dysfunction. *J Neurotrauma* 39:211–226. <https://doi.org/10.1089/neu.2021.0204>
11. Marinković P, Godinho L, Misgeld T (2015) Generation of Tissue Sections for Screening Thy1 Mouse Lines. *Cold Spring Harb Protoc* 2015:prot087684. <https://doi.org/10.1101/pdb.prot087684>
12. Petersen MA, Ryu JK, Akassoglou K (2018) Fibrinogen in neurological diseases: mechanisms, imaging and therapeutics. *Nat Rev Neurosci* 19:283–301. <https://doi.org/10.1038/nrn.2018.13>

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.